BIOGEN INC. Payments to Acquire Marketable Securities
BIOGEN INC. (BIIB) reported Payments to Acquire Marketable Securities of $1.16 billion for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2013-04-25
- BIOGEN INC. payments to acquire marketable securities for the quarter ending 2013-03-31 was $1.16B, a 71.42% increase year-over-year.
- BIOGEN INC. payments to acquire marketable securities for the quarter ending 2012-12-31 was $1.14B, a 3.26% increase year-over-year.
- BIOGEN INC. payments to acquire marketable securities for the quarter ending 2012-09-30 was $938.41M, a 15.51% increase year-over-year.
- BIOGEN INC. payments to acquire marketable securities for the quarter ending 2012-06-30 was $576.84M, a 33.68% decline year-over-year.
- BIOGEN INC. payments to acquire marketable securities for fiscal 2012 was $3.33B, a 9.81% decline from fiscal 2011.
- BIOGEN INC. payments to acquire marketable securities for fiscal 2011 was $3.70B, a 85.93% increase from fiscal 2010.
- BIOGEN INC. payments to acquire marketable securities for fiscal 2010 was $1.99B, a 43.96% decline from fiscal 2009.
- BIOGEN INC. payments to acquire marketable securities for fiscal 2009 was $3.55B, a 12.15% increase from fiscal 2008.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2013-03-31 | $1.16B 10-Q · filed 2013-04-25 | $2.30B derived: sum of 2 quarters · filed 2013-04-25 | $3.24B derived: sum of 3 quarters · filed 2013-04-25 | $3.82B derived: sum of 4 quarters · filed 2013-04-25 | |
| 2012-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $2.08B derived: sum of 2 quarters · filed 2013-02-05 | $2.66B derived: sum of 3 quarters · filed 2013-02-05 | $3.33B 10-K · filed 2013-02-05 | |
| 2012-09-30 | $938.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $1.52B derived: sum of 2 quarters · filed 2012-10-25 | $2.19B 10-Q · filed 2012-10-25 | $3.30B derived: sum of 4 quarters · filed 2013-04-25 | |
| 2012-06-30 | $576.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $1.25B 10-Q · filed 2012-07-24 | $2.36B derived: sum of 3 quarters · filed 2013-04-25 | $3.17B derived: sum of 4 quarters · filed 2013-04-25 | |
| 2012-03-31 | $677.09M 10-Q · filed 2013-04-25 | $1.78B derived: sum of 2 quarters · filed 2013-04-25 | $2.60B derived: sum of 3 quarters · filed 2013-04-25 | $3.47B derived: sum of 4 quarters · filed 2013-04-25 | |
| 2011-12-31 | $1.11B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $1.92B derived: sum of 2 quarters · filed 2013-02-05 | $2.79B derived: sum of 3 quarters · filed 2013-02-05 | $3.70B 10-K · filed 2013-02-05 | |
| 2011-09-30 | $812.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $1.68B derived: sum of 2 quarters · filed 2012-10-25 | $2.59B 10-Q · filed 2012-10-25 | $3.21B derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-06-30 | $869.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $1.78B 10-Q · filed 2012-07-24 | $2.40B derived: sum of 3 quarters · filed 2013-02-05 | $2.83B derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-03-31 | $908.73M 10-Q · filed 2012-05-01 | $1.53B derived: sum of 2 quarters · filed 2013-02-05 | $1.96B derived: sum of 3 quarters · filed 2013-02-05 | $2.20B derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | $616.63M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $1.05B derived: sum of 2 quarters · filed 2013-02-05 | $1.29B derived: sum of 3 quarters · filed 2013-02-05 | $1.99B 10-K · filed 2013-02-05 | |
| 2010-09-30 | $430.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $672.09M derived: sum of 2 quarters · filed 2011-10-28 | $1.37B 10-Q · filed 2011-10-28 | $1.92B derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | $241.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $941.27M 10-Q · filed 2011-07-26 | $1.49B derived: sum of 3 quarters · filed 2012-02-03 | $2.62B derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-03-31 | $699.68M 10-Q · filed 2011-04-21 | $1.25B derived: sum of 2 quarters · filed 2012-02-03 | $2.38B derived: sum of 3 quarters · filed 2012-02-03 | $3.14B derived: sum of 4 quarters · filed 2012-02-03 | |
| 2009-12-31 | $546.96M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $1.68B derived: sum of 2 quarters · filed 2012-02-03 | $2.44B derived: sum of 3 quarters · filed 2012-02-03 | $3.55B 10-K · filed 2012-02-03 | |
| 2009-09-30 | $1.13B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $1.89B derived: sum of 2 quarters · filed 2010-10-26 | $3.00B 10-Q · filed 2010-10-26 | $4.36B derived: sum of 4 quarters · filed 2011-02-04 | |
| 2009-06-30 | $759.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $1.87B 10-Q · filed 2010-07-20 | -$1.87B 10-Q · filed 2009-07-17 | $3.23B derived: sum of 3 quarters · filed 2011-02-04 | $6.09B derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $1.11B 10-Q · filed 2010-04-20 | $2.47B derived: sum of 2 quarters · filed 2011-02-04 | $5.33B derived: sum of 3 quarters · filed 2011-02-04 | ||
| 2008-12-31 | $1.36B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $4.22B derived: sum of 2 quarters · filed 2011-02-04 | $3.16B 10-K · filed 2011-02-04 | ||
| 2008-09-30 | $2.86B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $1.80B 10-Q · filed 2009-10-21 | |||
| 2008-06-30 | -$1.06B 10-Q · filed 2009-07-17 | ||||
| 2007-12-31 | $2.95B 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |